Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Hematology & Oncology Physician in Sacramento, CA
NPI: 1033237987Primary Practice Location
UNIVERSITY OF CALIFORNIA DAVIS MEDICAL CENTER
4301 X St, Sacramento, CA
Primary Employer
Regents of the University of CA
health.ucdavis.edu
HQ Phone
Get M.D., PHD Edward's Phone Numberphone_androidMobile
Get M.D., PHD Edward's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2012 - 2026
MI State Medical License
2005 - 2015
American Board of Internal Medicine
Medical Oncology
Harvard University
AB • Chemistry
1993 - 1997
Renaissance School of Medicine at Stony Brook University
stonybrook.edu
Medical School
Until 2005
University of Michigan
Residency • Internal Medicine
2005 - 2007
Fellowship • Hematology and Medical Oncology
2007 - 2011
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 92 | 210 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 61 | 99 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 33 | 33 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 23 | 30 |
| 5 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 20 | 58 |
Authors: Kim, Edward J, Helfman, David M
Journal: J Biol Chem
Publication Date: 2003-05-19
Lead Sponsor: University of California, Davis
Collaborators: Bristol-Myers Squibb, National Cancer Institute (NCI), Dynavax Technologies Corporation
Intervention / Treatment: BIOLOGICAL: Nivolumab, RADIATION: Radiation Therapy, DRUG: TLR9 Agonist SD-101
Lead Sponsor: Edward Kim
Collaborators: Bristol-Myers Squibb, National Cancer Institute (NCI)
Intervention / Treatment: BIOLOGICAL: Nivolumab, DRUG: IDO1 Inhibitor BMS-986205
Lead Sponsor: Robin Kate Kelley
Collaborators: Bristol-Myers Squibb, Bayer
Intervention / Treatment: BIOLOGICAL: Nivolumab, DRUG: Sorafenib
